Physician profile
Hansen Su
NPI 1952372591
$5,934.24
in general payments reported to CMS, 2019-2025
29 companies · $26.06 in 2025
The $26.06 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,418 · 2020: $773 · 2021: $577 · 2022: $648 · 2023: $417 · 2024: $75.70 · 2025: $26.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $491 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $491.07 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,228.72 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $931.45 | 2019-2023 | Rexulti |
| Alkermes, INC. | $687.37 | 2019-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $674.88 | 2019-2025 | Austedo, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $354.65 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $300.13 | 2019-2023 | Ingrezza |
| Indivior INC. | $279.58 | 2019-2023 | Perseris |
| Lundbeck LLC | $244.27 | 2019-2023 | Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $157.90 | 2019-2022 | |
| Abbvie INC. | $149.98 | 2021-2024 | Vraylar |
| Allergan, INC. | $146.82 | 2019-2020 | |
| Shire North American Group INC | $101.10 | 2019 | |
| Vanda Pharmaceuticals INC. | $96.68 | 2019-2020 | |
| Tris Pharma INC | $84.02 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $72.35 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $57.78 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $54.62 | 2019 | |
| Jazz Pharmaceuticals INC. | $48.20 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $46.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $44.02 | 2024 | Cobenfy |
| Corium, LLC | $26.77 | 2023-2024 | Azstarys |
| Neos Therapeutics, Lp | $26.36 | 2019 | |
| Adlon Therapeutics L.P. | $25.55 | 2019 | |
| Supernus Pharmaceuticals, INC. | $23.49 | 2023 | Qelbree |
| Bausch Health US, LLC | $17.01 | 2020 | |
| Merck Sharp & Dohme LLC | $14.92 | 2020 | |
| Almatica Pharma LLC | $13.59 | 2023 | Loreev Xr |
| Genentech USA, INC. | $13.32 | 2019 | |
| Validus Pharmaceuticals LLC | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hansen Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.